Home › Borstkanker › Oregon › Portland
Borstkanker klinische studies in Portland, OR
33 studies voor Borstkanker zoeken deelnemers op locaties in en rond Portland (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RekruterenFase 3
- Oregon Health & Science University, Knight Cancer Institute, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruterenFase 1/2
- Oregon Health & Science University (OHSU), Portland
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
RekruterenFase 3
- Northwest Cancer Specialists, Portland
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mijl verwijderd
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
RekruterenFase 1/2
- Compass Oncology - Rose Quarter Cancer Center, Portland
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RekruterenFase 1
- Research Site, Portland
Study of AVZO-021 in Patients With Advanced Solid Tumors
RekruterenFase 1/2
- Avenzo Therapeutics Recruiting Site, Portland
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RekruterenFase 3
- Providence Portland Medical Center ( Site 0044), Portland
- Providence St. Vincent Medical Center ( Site 0081), Portland
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
RekruterenFase 2
- Oregon Health and Science University, Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RekruterenFase 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
RekruterenFase 3
- Clinical Trial Site, Portland
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RekruterenFase 3
- Oregon Health and Science University, Portland
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
RekruterenFase 2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RekruterenFase 3
- Providence Portland Medical Center, Portland
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RekruterenFase 3
- Providence Cancer Institute Franz Clinic, Portland
- Providence Cancer Institute Franz Clinic, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruterenFase 1
- Providence Portland Medical Center, Portland
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekruterenFase 1
- Providence Cancer Institute, Portland
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RekruterenFase 3
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Cancer Clinic - Westside;Investigation Drug Services Pharmacy, Portland
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RekruterenFase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- en nog 2
A Study of MGC026 in Participants With Advanced Solid Tumors
RekruterenFase 1
- Providence Cancer Institute, Portland
E-Mindfulness Approaches for Living After Breast Cancer
RekruterenFase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- en nog 1
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruterenFase 1/2
- Compass Oncology - Rose Quarter, Portland
Identifying and Caring for Individuals With Inherited Cancer Syndrome
RekruterenGezonde vrijwilligers welkom
- Providence Portland Medical Center, Portland
- OHSU Knight Cancer Institute, Portland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekruterenFase 1/2
- Providence Cancer Institute Franz Clinic, Portland
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
RekruterenFase 2
- OHSU Knight Cancer Institute, Portland
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekruterenFase 2
- Oregon Health & Science Institute (OHSU), Portland
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RekruterenFase 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- en nog 1
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekruterenObservatieonderzoek
- Kaiser Permanente Northwest, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Oregon Health Sciences University, Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruterenObservatieonderzoek
- Massive Bio SYNERGY-AI site, Portland
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
RekruterenFase 3
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
RekruterenObservatieonderzoek
- Legacy Good Samaritan Medical Center, Portland
EMBRACE: Exercising Together
RekruterenFase 2Gezonde vrijwilligers welkom
- OHSU Knight Cancer Institute, Portland
Borstkanker studies in andere steden
- New York City, NY136 studies
- Houston, TX126 studies
- Boston, MA112 studies
- Nashville, TN81 studies
- Los Angeles, CA73 studies
- Edison, NJ68 studies
- St. Louis, MO64 studies
- Queens, NY64 studies
- Durham, NC64 studies
- Chicago, IL59 studies
- Philadelphia, PA56 studies
- Dallas, TX55 studies
Andere studies in Portland
- Niet-kleincellige longkanker46 studies
- Kanker (alle vormen)34 studies
- Prostaatkanker33 studies
- Metastatische kanker29 studies
- Colorectale kanker28 studies
- Eierstokkanker27 studies
- Longkanker26 studies
- Acute myeloïde leukemie25 studies
- Endometriumkanker24 studies
- Plaveiselcelcarcinoom van hoofd en hals19 studies
- Aldermeesklierkanker19 studies
- Hartfalen17 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.